Trial Profile
A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 24 Aug 2020 Status changed from completed to discontinued.
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.